净利润增长近5成，川宁生物去年业绩创上市新高

Core Viewpoint - The company Chuaning Biological has reported significant growth in revenue and net profit, driven by increased sales and prices of its main products, as well as improvements in manufacturing processes through AI technology [1][2][3] Financial Performance - In 2024, Chuaning Biological achieved a revenue of 5.758 billion yuan, a year-on-year increase of 19.38%, and a net profit of 1.4 billion yuan, up 48.88%, both reaching historical highs [1] - The company's revenue from pharmaceutical intermediates was 5.356 billion yuan, an increase of over 900 million yuan from the previous year, with a year-on-year growth rate exceeding 20% [1] - The gross profit margin for the pharmaceutical intermediates business improved by 5.42 percentage points to 38.63% [1] Product and Market Insights - Chuaning Biological specializes in the research and sales of antibiotic intermediates, including three main categories: thiocyanate erythromycin, cephalosporin intermediates, and penicillin derivatives [1] - The revenue contribution from the three main products to total revenue was 32.35%, 24.96%, and 41.95%, respectively [1] AI and Technological Advancements - The company has begun utilizing AI to enhance manufacturing processes, achieving dynamic control in the production line of thiocyanate erythromycin, which has led to increased fermentation yields and reduced production fluctuations [2] - Chuaning Biological plans to continue leveraging AI and synthetic biology technologies to further stabilize production fluctuations and improve extraction yields by 2025 [3] Strategic Investments - In February of the previous year, Chuaning Biological acquired a 16.67% stake in Shanghai Jinchang Technology, which focuses on AI applications in biotechnology [2]